Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04LKS
|
|||
| Former ID |
DNCL003509
|
|||
| Drug Name |
Ruxolitinib
|
|||
| Synonyms |
Ruxolitinib (JAK inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Essential thrombocythemia [ICD-11: 3B63.1Z; ICD-9: 238.71, 289.9] | Approved | [1] | |
| High-risk myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Approved | [2], [3], [4], [5] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [2], [6] | ||
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 1/2 | [7] | ||
| Vitiligo [ICD-11: ED63.0; ICD-10: L80-L99, L80; ICD-9: 709.01] | Phase 1/2 | [7] | ||
| Company |
Incyte
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18N6
|
|||
| Canonical SMILES |
C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
|
|||
| InChI |
1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
|
|||
| InChIKey |
HFNKQEVNSGCOJV-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 941678-49-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
81071277, 85921742, 104253171, 131480859, 134339114, 134449640, 135263142, 135626684, 135693443, 135727401, 136367406, 136378506, 136920365, 136959525, 137168066, 137237509, 137275864, 137875640, 144116074, 152212763, 152258834, 152344048, 152344083, 160645455, 160647685, 162011537, 162038073, 162197164, 163913900, 164193924, 164764917, 165238055, 170502151, 172919539, 174006685, 174474441, 175267965, 175427129, 177748964, 178102315, 186005338, 188376260, 198992749, 208265517, 223617460, 223723945, 224411802, 226532797, 247725985, 249737056
|
|||
| ChEBI ID |
CHEBI:66919
|
|||
| ADReCS Drug ID | BADD_D01978 | |||
| SuperDrug ATC ID |
L01XE18
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688). | |||
| REF 3 | ClinicalTrials.gov (NCT02038036) Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.. U.S. National Institutes of Health. | |||
| REF 4 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 6 | ClinicalTrials.gov (NCT02117479) Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1). U.S. National Institutes of Health. | |||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 8 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
| REF 9 | Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.